Highflyer 2016?
Array BioPharma To Present At The Cantor Fitzgerald 2nd Annual Healthcare Conference
Donnerstag, 07.07.2016 18:36 von PR Newswire
http://www.ariva.de/news/...sent-at-the-cantor-fitzgerald-2nd-5806351
http://finance.yahoo.com/news/...ort-financial-results-205600045.html
Date:
§
Thursday, August 4, 2016
Time:
§
9:00 a.m. Eastern Time
Toll-Free:
§
(844) 464-3927
Toll:
§
(765) 507-2598
Pass Code:
55520532
§
Webcast, including Replay and Conference Call Slides:
http://edge.media-server.com/m/p/9vx5kngz
Array BioPharma Reports Financial Results For The Fourth Quarter And Full Year Of Fiscal 2016
Donnerstag, 04.08.2016 14:06 von PR Newswire
http://www.ariva.de/news/...-financial-results-for-the-fourth-5837117
die News dazu...;-)
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
Selumetinib did not meet trial endpoint of progression-free survival in KRASm NSCLC patients
http://investor.arraybiopharma.com/...irol-newsArticle&ID=2194007
Erst Keryx, dann hier,
hoffentlich nicht noch AEZS,
dann fliegen aber PC's durch die Fenster, und Familien Tragödien sind vorprogramiert.
Na, Cobra, was meinste?
Gruß
Heron
noch dabei ??
Array expects COLUMBUS top-line results during the third quarter of 2016.
COLUMBUS: Global Phase 3 trial of binimetinib plus encorafenib versus vemurafenib in BRAF-mutant melanoma patients
http://investor.arraybiopharma.com/...ing&cat=news&id=2192986
Array BioPharma To Present At The Wells Fargo Securities Healthcare Conference
Mittwoch, 31.08.2016 15:05 von PR Newswire
Wednesday, September 7, 2016
http://www.ariva.de/news/...ent-at-the-wells-fargo-securities-5861945
Array BioPharma Announces FDA Acceptance of Binimetinib NDA for Patients with Advanced NRAS-Mutant Melanoma
Donnerstag, 01.09.2016 14:05 von PR Newswire
http://www.ariva.de/news/...fda-acceptance-of-binimetinib-nda-5863292
http://www.ariva.de/news/...e-fabre-announce-columbus-phase-3-5889996
http://www.nasdaqtrader.com/trader.aspx?id=tradehalts
+cc
Array will hold a conference call on Monday, September 26, 2016 at 9:00 a.m. Eastern Time to discuss these results.
wird jetzt gleich interesant......
14.9 months vs 7.3 PFS (primary). 14.9 months vs 9.6 PFS (secondary)
http://www.ariva.de/news/...e-fabre-announce-columbus-phase-3-5889996
http://secfilings.nasdaq.com/...%20INC&FormType=8-K&View=html
Date:
§
Monday, September 26, 2016
Time:
§
9:00 a.m. Eastern Time
Toll-Free:
§
(844) 464-3927
Toll:
§
(765) 507-2598
Pass Code:
88687420
§
Webcast, including Replay and Conference Call Slides: http://edge.media-server.com/m/p/f2gpqhkz
nachhaltig steigende Kurse sind viel besser.
Alles was schnell steigt, kann genauso schnell wieder den Bach runter gehen.
http://www.arraybiopharma.com/product-pipeline/
muss ja nicht heute die großen gewinne kommen.......... ich sage immer bisschen investieren und paar jahre abwarten..........
Was meint ihr zur Shortquote? Ist doch schon heftig. Da haben sich wohl einige verspekuliert.